亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial

鲁索利替尼 医学 骨髓纤维化 骨髓增生性肿瘤 内科学 人口 随机对照试验 胃肠病学 外科 骨髓 环境卫生
作者
John O Mascarenhas,Ronald Hoffman,Moshe Talpaz,Aaron Thomas Gerds,Brady Lee Stein,Vikas K Gupta,Anita Szőke,Mark W. Drummond,Alexander S. Pristupa,Tanya Granston,Robert Daly,Suliman Al‐Fayoumi,Jennifer A. Callahan,Jack W. Singer,Jason R. Gotlib,Catriona H. M. Jamieson,Claire N. Harrison,Ruben A. Mesa,Srđan Verstovšek
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:4 (5): 652-652 被引量:435
标识
DOI:10.1001/jamaoncol.2017.5818
摘要

Importance: Myelofibrosis is a hematologic malignancy characterized by splenomegaly and debilitating symptoms. Thrombocytopenia is a poor prognostic feature and limits use of Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor ruxolitinib. Objective: To compare the efficacy and safety of JAK2 inhibitor pacritinib with that of best available therapy (BAT), including ruxolitinib, in patients with myelofibrosis and thrombocytopenia. Design, Setting, and Participants: For this phase 3 randomized international multicenter study-the PERSIST-2 study-of pacritinib vs BAT, 311 patients with myelofibrosis and platelet count 100 × 109/L or less were recruited for analysis. Crossover from BAT was allowed after week 24 or for progression of splenomegaly. Interventions: Patients were randomized 1:1:1 to pacritinib 400 mg once daily, pacritinib 200 mg twice daily, or BAT. Main Outcomes and Measures: Coprimary end points were rates of patients achieving 35% or more spleen volume reduction (SVR) and 50% or more reduction in total symptom score (TSS) at week 24. Efficacy analyses were performed on the intention-to-treat efficacy population, comprising all patients with a randomization date allowing for week 24 data. Results: Overall, 311 patients (mean [SD] age, 63.70 [9.08] years; 171 men [55%] and 140 women [45%]) were included in the study; 149 patients (48%) had prior ruxolitinib. The most common BAT was ruxolitinib (44 patients [45%]); 19 patients (19%) received watchful-waiting only. The intention-to-treat efficacy population included 75 patients randomized to pacritinib once daily; 74, pacritinib twice daily, and 72, BAT. Pacritinib (arms combined) was more effective than BAT for 35% or more SVR (27 patients [18%] vs 2 patients [3%]; P = .001) and had a nonsignificantly greater rate of 50% or more reduction in TSS (37 patients [25%] vs 10 patients [14%]; P = .08). Pacritinib twice daily led to significant improvements in both end points over BAT (≥35% SVR: 16 patients [22%] vs 2 patients [3%]; P = .001; ≥50% reduction in TSS: 24 patients [32%] vs 10 patients [14%]; P = .01). Clinical improvement in hemoglobin and reduction in transfusion burden were greatest with pacritinib twice daily. For pacritinib once daily, pacritinib twice daily, and BAT, the most common (>10%) grade 3 or 4 adverse events were thrombocytopenia (32 patients [31%], 34 patients [32%], 18 patients [18%]), and anemia (28 patients [27%], 23 patients [22%], 14 patients [14%]). In the pacritinib once daily, twice daily, and BAT arms, discontinuation owing to adverse events occurred in 15 patients (14%), 10 patients (9%), and 4 patients (4%). Conclusions and Relevance: In patients with myelofibrosis and thrombocytopenia, including those with prior anti-JAK therapy, pacritinib twice daily was more effective than BAT, including ruxolitinib, for reducing splenomegaly and symptoms. Trial Registration: clinicaltrials.gov Identifier: NCT02055781.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
6秒前
11秒前
waui完成签到 ,获得积分10
12秒前
18秒前
小巧的寒烟完成签到,获得积分10
18秒前
Rain完成签到,获得积分20
18秒前
Rain发布了新的文献求助10
22秒前
无极微光的应助被难过花瓣采纳,获得20
22秒前
22秒前
28秒前
眼中星光完成签到,获得积分10
29秒前
40秒前
cc对应助文件撤销了驳回
40秒前
41秒前
停騮_ 完成签到,获得积分10
41秒前
搜集达人的应助被锅包肉采纳,获得10
42秒前
危机的奄完成签到,获得积分10
42秒前
成就书雪完成签到,获得积分0
43秒前
45秒前
哇二木耶完成签到,获得积分10
52秒前
53秒前
hogjluo完成签到,获得积分10
55秒前
追寻书本完成签到,获得积分10
56秒前
57秒前
锅包肉发布了新的文献求助10
1分钟前
chen01hang的应助被EShiroYuki采纳,获得120
1分钟前
星空完成签到 ,获得积分20
1分钟前
1分钟前
1分钟前
FashionBoy的应助被cc采纳,获得10
1分钟前
1分钟前
李糯的饺子完成签到,获得积分10
1分钟前
1分钟前
VT完成签到,获得积分10
1分钟前
顾矜的应助被锅包肉采纳,获得10
1分钟前
华无剑的应助被VT采纳,获得10
1分钟前
健康的兰完成签到,获得积分10
1分钟前
所所的应助被Culto采纳,获得10
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165954
求助须知:如何正确求助?哪些是违规求助? 9559332
关于积分的说明 21749951
捐赠科研通 7756726
什么是DOI,文献DOI怎么找? 3429092
关于科研通互助平台的介绍 2553386
邀请新用户注册赠送积分活动 2473657